Drug profile · INN
pertuzumab, trastuzumab, and hyaluronidase-zzxf
PHESGO
pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — pertuzumab, trastuzumab, and hyaluronidase-zzxf
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is pertuzumab, trastuzumab, and hyaluronidase-zzxf?
pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) is an FDA-listed pharmaceutical active ingredient. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for pertuzumab, trastuzumab, and hyaluronidase-zzxf?
PHESGO is a marketed brand name for pertuzumab, trastuzumab, and hyaluronidase-zzxf. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pertuzumab, trastuzumab, and hyaluronidase-zzxf?
pertuzumab, trastuzumab, and hyaluronidase-zzxf has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.